BACKGROUND: Oseltamivir, a widely used anti-influenza drug, is hydrolytically activated by carboxylesterase 1 (CES1). The expression of this carboxylesterase is developmentally regulated. This study was performed to determine when after birth infants acquire competence of activating this prodrug. METHODS: Liver tissue samples were collected and divided into 5 age groups: group 1 (1-31 d old), group 2 (35-70 d old), group 3 (89-119 d old), group 4 (123-198 d old), and group 5 (>18 years of age). These samples were analyzed for oseltamivir hydrolysis and CES1 expression. RESULTS: Liver samples in group 1 expressed the lowest level of CES1 with the lowest hydrolytic activity toward oseltamivir. A 4-7-fold increase between groups 1 and 2 (1-31 vs 35-70 d of age) was detected in the hydrolysis and expression analyses, respectively. Liver samples in the other 3 pediatric groups (35-198 d of age) exhibited similar expression and hydrolysis levels. Overall, liver samples in group 1 had CES1 expression and hydrolysis levels that were 10% of those of adults, whereas liver samples in the other 3 pediatric groups had levels that were ∼50% of adult levels. CONCLUSIONS: The post-neonatal surge in CES1 expression ensures the hydrolytic capacity to be gained rapidly after birth in infants, but the larger variability during this period suggests that caution should be exercised on the extrapolated dosing regimens of ester drugs from other age groups.
BACKGROUND:Oseltamivir, a widely used anti-influenza drug, is hydrolytically activated by carboxylesterase 1 (CES1). The expression of this carboxylesterase is developmentally regulated. This study was performed to determine when after birth infants acquire competence of activating this prodrug. METHODS: Liver tissue samples were collected and divided into 5 age groups: group 1 (1-31 d old), group 2 (35-70 d old), group 3 (89-119 d old), group 4 (123-198 d old), and group 5 (>18 years of age). These samples were analyzed for oseltamivir hydrolysis and CES1 expression. RESULTS: Liver samples in group 1 expressed the lowest level of CES1 with the lowest hydrolytic activity toward oseltamivir. A 4-7-fold increase between groups 1 and 2 (1-31 vs 35-70 d of age) was detected in the hydrolysis and expression analyses, respectively. Liver samples in the other 3 pediatric groups (35-198 d of age) exhibited similar expression and hydrolysis levels. Overall, liver samples in group 1 had CES1 expression and hydrolysis levels that were 10% of those of adults, whereas liver samples in the other 3 pediatric groups had levels that were ∼50% of adult levels. CONCLUSIONS: The post-neonatal surge in CES1 expression ensures the hydrolytic capacity to be gained rapidly after birth in infants, but the larger variability during this period suggests that caution should be exercised on the extrapolated dosing regimens of ester drugs from other age groups.
Authors: Wiku Adisasmito; Paul K S Chan; Nelson Lee; Ahmet Faik Oner; Viktor Gasimov; Faik Aghayev; Mukhtiar Zaman; Ebun Bamgboye; Nazim Dogan; Richard Coker; Kathryn Starzyk; Nancy A Dreyer; Stephen Toovey Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Sonal P Sanghani; Sara K Quinney; Tyler B Fredenburg; Wilhelmina I Davis; Daryl J Murry; William F Bosron Journal: Drug Metab Dispos Date: 2004-05 Impact factor: 3.922
Authors: Hao-Jie Zhu; Taimour Y Langaee; Yan Gong; Xinwen Wang; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson; John S Markowitz Journal: Eur J Clin Pharmacol Date: 2016-02-26 Impact factor: 2.953
Authors: Christopher McPherson; Barbara Warner; David A Hunstad; Alexis Elward; Edward P Acosta Journal: J Infect Dis Date: 2012-07-17 Impact factor: 5.226
Authors: Da Xiao; Deshi Shi; Dongfang Yang; Benjamin Barthel; Tad H Koch; Bingfang Yan Journal: Biochem Pharmacol Date: 2012-12-07 Impact factor: 5.858
Authors: Srinivas R Chirapu; Jonathan N Bauman; Heather Eng; Theunis C Goosen; Timothy J Strelevitz; Subhash C Sinha; Robert L Dow; M G Finn Journal: Bioorg Med Chem Lett Date: 2014-01-08 Impact factor: 2.823